DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on October 4, 2006; DOI: 10.1124/dmd.106.012492


0090-9556/07/3501-1-8$20.00
DMD 35:1-8, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.012492v1
35/1/1    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gonzalez, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gonzalez, F. J.

CYP2E1

Frank J. Gonzalez

Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Bernard B. Brodie's laboratory was the first to examine the mechanisms of drug-induced toxicity at the molecular level. They found that acetaminophen hepatotoxicity was due to the metabolic activation of the drug to a highly reactive toxic metabolite that depleted cellular glutathione and covalently bound to protein. Subsequent studies revealed that activation of acetaminophen to an active metabolite is primarily carried out by CYP2E1, an ethanol-inducible cytochrome P450 that was first suggested by characterization of the microsomal ethanol oxidation system. CYP2E1 is developmentally regulated, under liver-specific control, and undergoes substrate-induced protein stabilization. It is also regulated by starvation and diabetes through insulin-dependent mRNA stabilization. In addition to acetaminophen, CYP2E1 metabolically activates a large number of low Mr toxicants and carcinogens and thus is of great toxicological importance. The mechanism of regulation CYP2E1 and its role in acetaminophen toxicity will be discussed.


Address correspondence to: Frank J. Gonzalez, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Building 37/Room 3106, Bethesda, MD 20892. E-mail: fjgonz{at}helix.nih.gov




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
P. J. Murphy
The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984-2008
Drug Metab. Dispos., October 1, 2008; 36(10): 1977 - 1982.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. A. Felmlee, H.-K. Lon, F. J. Gonzalez, and A.-M. Yu
Cytochrome P450 Expression and Regulation in CYP3A4/CYP2D6 Double Transgenic Humanized Mice
Drug Metab. Dispos., February 1, 2008; 36(2): 435 - 441.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
M. H. Court
A Pharmacogenomics Primer
J. Clin. Pharmacol., September 1, 2007; 47(9): 1087 - 1103.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Datta-Mannan, D. R. Witcher, Y. Tang, J. Watkins, and V. J. Wroblewski
Monoclonal Antibody Clearance: IMPACT OF MODULATING THE INTERACTION OF IgG WITH THE NEONATAL Fc RECEPTOR
J. Biol. Chem., January 19, 2007; 282(3): 1709 - 1717.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.